Financial News:
Forbes Healthcare
| Making Genentech Disappear One of the most important companies of the past 30 years could lose its identity inside Roche. That's not altogether a bad thing. |
| Merck, Schering Take A Hit The drug makers disappoint the Street while trying to combat bad news from the Vytorin study. |
| Another Blow For Merck And Schering Merck and Schering-Plough delay their earnings calls for the release of a study about their controversial cholesterol drug. |
| Primary Health Care Coughs Up Its Vitamins The Australian operator of medical clinics decides that the pills business it acquired with Symbion Health is not a fit, so it is selling it on to Sanofi-Aventis for $546.6 million. |
| Key Vytorin Results Expected Merck and Schering-Plough delay their earnings calls for the release of a study about their controversial cholesterol drug. |